


MAPK/ERK 伝達経路 関連化合物



●アルツハイマー病、パーキンソン病、筋萎縮性側索硬化症(ALS)および種々のタイプのガンを含む多くのヒト疾患の発症に関与しているMAPKシグナル伝達経路の関連化合物を提供。

●MAPKファミリーは、増殖、分化、発達、形質転換、アポトーシスなどの細胞プログラムにおいて重要な役割を果たしています。

●ERK、JNK、MEK、p38 MAPK、Raf、RSK、MNKなどをターゲット。


●高純度を保証するためにNMRおよびHPLCにより分析。

MAPK/ERK 伝達経路 関連化合物

~MAPK/ERK Pathway~

HY-50846

SCH772984




SCH772984 potently inhibits ERK1 and ERK2 activity with IC50 values of 4 and 1 nM, respectively.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 942183-80-4)

HY-15947

GDC-0994




GDC-0994 is an orally bioavailable inhibitor selective for ERK kinase activity with IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 1453848-26-4)

HY-14443

XMD8-92




XMD8-92 is a highly selective ERK5/BMK1 inhibitor with dissociation constant (Kd) value of 80 nM.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 1234480-50-2)

HY-14178

VX-11e




VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK with Ki < 2 nM.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 896720-20-0)

HY-12275

FR 180204




FR 180204 is an ATP-competitive, selective ERK inhibitor with Ki of 0.31 μ M and 0.14 μ M for ERK1 and ERK2, respectively.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 865362-74-9)

HY-100627A

APS-2-79 hydrochloride



HCl


APS 2-79 hydrochloride is an antagonist of MEK phosphorylation by RAF through direct binding of the KSR active site with IC50 values of 120 \pm 23 and 418 \pm 40 nM for KSR2 and MEK1, respectively.

Target: **ERK**
Effect: **Antagonist**

(CAS No. : 2002381-31-7)

HY-N0431

Astragaloside IV




Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteinases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 84687-43-4)

HY-15615A

TIC10




TIC10 is a potent, orally active, and stable TRAIL inducer, also inhibits Akt and ERK activity.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 1616632-77-9)

HY-19696A

Tauroursodeoxycholate Sodium




Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by reducing proliferation and inducing apoptosis of smooth muscle cells by suppression of ERK via PKC α -mediated MKP-1 induction.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 35807-85-3)

HY-15816

VRT752271




VRT752271 is a pyrrole inhibitors of ERK protein kinase.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 869886-67-9)

HY-100627

APS-2-79




APS-2-79 is an antagonist of MEK phosphorylation by RAF through direct binding of the KSR active site.

Target: **ERK**
Effect: **Antagonist**

(CAS No. : 2002381-25-9)

HY-14403

ERK5-IN-1




ERK5-IN-1 exhibits potent inhibition of ERK5 with cellular EC50 values of 0.19 μ M and enzymatic IC50 values of 0.087 μ M and of LRRK2[G2019S] with enzymatic IC50 values of 0.026 μ M.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 1234479-76-5)

HY-N0590

Corynoxene




Corynoxene is a potent ERK1/2 inhibitor of key PDGF-BB-induced VSMC proliferation; a useful and prospective compound in the prevention and treatment for vascular diseases.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 630-94-4)

HY-18932

DEL-22379



DEL-22379 is an ERK dimerization inhibitor with IC50 of 0.5 μ M.


Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 181223-80-3)

(全ての製品は試験研究用です。試験研究以外の用途にはご利用いただけません。)

MAPK/ERK 伝達経路 関連化合物

~MAPK/ERK Pathway~




HY-15665

XMD17-109

XMD17-109 is a novel, specific ERK-5 inhibitor, which inhibits the ERK5-mediated AP1 transcriptional activity at 30 μ M, and has an EC₅₀ of 4.2 μ M.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 1435488-37-1)




HY-N0893

Tetrahydrocurcumin

Tetrahydrocurcumin is one of the major metabolites of Curcumin; apoptosis inducer and has been demonstrated to be an antioxidant.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 36062-04-1)




HY-N2312

Mogrol

Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 88930-15-8)




HY-N2149

Tomatidine

Tomatidine inhibits the phosphorylation of ERK, Akt, and the nuclear content of NF- κ B.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 77-59-8)




HY-N0052A

Sanguinarine chloride

Sanguinarine (chloride) is natural product.

Target: **ERK**
Effect: **Activator**

(CAS No. : 5578-73-4)




HY-15615

TIC10 isomer

TIC10 isomer(ONC201 isomer) is an isomer of TIC10; TIC10 is a potent, orally active, and stable small molecule that transcriptionally induces TRAIL in a p53-independent manner and crosses the blood-brain barrier.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 41276-02-2)




HY-N0052

Sanguinarine

Sanguinarine(Pseudocheleerythrine) is a benzophenanthridine alkaloid which has anti-microbial, anti-oxidant and anti-inflammatory properties; specific inhibitor of Rac1b.

Target: **ERK**
Effect: **Activator**

(CAS No. : 2447-54-3)




HY-N0371

Pachymic acid

Pachymic acid is a lanostane-type triterpenoid, which possesses anti-emetic, anti-inflammatory, and anti-cancer properties.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 29070-92-6)




HY-15947A

GDC-0994 hydrochloride

GDC-0994 hydrochloride is an orally bioavailable inhibitor selective for ERK kinase activity with IC₅₀ of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 2070009-58-2)




HY-N0300

Tetrahydropalmatine

Tetrahydropalmatine, an active component isolated from corydalis (a Chinese herbal medicine), possesses analgesic effects.

Target: **ERK**
Effect: **Inhibitor**

(CAS No. : 2934-97-6)




HY-12041

SP600125

SP600125 is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC₅₀ of 40 nM, 40 nM and 90 nM, respectively.

Target: **JNK**
Effect: **Inhibitor**

(CAS No. : 129-56-6)




HY-18982

Anisomycin

Anisomycin is a pyrrolidine antibiotic, acts as an anti-fungal antibiotic which inhibits Protein Synthesis, also is a potent activator of SAPKs/JNKs.

Target: **JNK**
Effect: **Activator**

(CAS No. : 22862-76-6)




HY-15495

CC-930

CC-930 is a potent JNK1/JNK2/JNK3 inhibitor with IC₅₀ values of 61/7/6 nM, respectively, and used for the treatment of fibrotic and inflammatory indications.

Target: **JNK**
Effect: **Inhibitor**

(CAS No. : 899805-25-5)



HY-13319

JNK-IN-8

JNK-IN-8 is a potent JNK inhibitor with IC₅₀ of 4.7 nM, 18.7 nM, and 1 nM for JNK1, JNK2, and JNK3, respectively.

Target: **JNK**
Effect: **Inhibitor**

(CAS No. : 1410880-22-6)

(全ての製品は試験研究用です。試験研究以外の用途にはご利用いただけません。)

MAPK/ERK 伝達経路 関連化合物

～MAPK/ERK Pathway～

HY-P0069

D-JNKI-1

D-JNKI-1 is a specific inhibitor of JNK, and strongly interferes with JNK activation.


—GKKKKRRRRPPRRKPTTLNLFPPQVPRSGDT

Target: **JNK**
Effect: **Inhibitor**

HY-15617

JNK-IN-7

JNK-IN-7 is a relatively selective JNKs inhibitor (IC₅₀= 1.54/1.99/0.75 for JNK1/2/3); also bound to IRAK1, PIK3C3, PIP5K3 and PIP4K2C.




Target: **JNK**
Effect: **Inhibitor**

(CAS No. : 1408064-71-0)

HY-13022

CC-401 hydrochloride

CC-401 hydrochloride is a potent inhibitor of all three forms of JNK with K_i of 25 to 50 nM.




Target: **JNK**
Effect: **Inhibitor**

(CAS No. : 1438391-30-0)

HY-11010

AS601245

AS601245 is an inhibitor of the c-Jun NH₂-terminal kinase (JNK) (hJNK1: IC₅₀=150nM, hJNK2: IC₅₀=220nM and hJNK3: IC₅₀=70 nM), has neuroprotective properties.




Target: **JNK**
Effect: **Inhibitor**

(CAS No. : 345987-15-7)

HY-12829

SR-3306

SR-3306 is a brain penetrant small molecule JNK inhibitor from the aminopyrimidine class.




Target: **JNK**
Effect: **Inhibitor**

(CAS No. : 1128096-91-2)

HY-15027

5-Aminosalicylic acid

5-Aminosalicylic acid is an anti-inflammatory compound.




Target: **JNK**
Effect: **Inhibitor**

(CAS No. : 89-57-6)

HY-100233

IQ-1S free acid

IQ-1S (free acid) is an inhibitor of JNK kinases, with a preference for JNK3. K_d values for IQ-1S binding to JNK 1, 2 and 3 binding are 390, 360 and 87 nM, respectively.




Target: **JNK**
Effect: **Inhibitor**

(CAS No. : 23146-22-7)

HY-N0431

Astragaloside IV

Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.




Target: **JNK**
Effect: **Inhibitor**

(CAS No. : 84687-43-4)

HY-N0176

Dihydroartemisinin

Dihydroartemisinin, one of the most active artemisinin derivative, exhibits anticancer activity in a number of human cancer cells.




Target: **JNK**
Effect: **Activator**

(CAS No. : 71939-50-9)

HY-14761

AS 602801

AS 602801 is an ATP-competitive JNK inhibitor with IC₅₀ of 80 nM, 90 nM, and 230 nM for JNK1, JNK2, and JNK3, respectively.




Target: **JNK**
Effect: **Inhibitor**

(CAS No. : 848344-36-5)

HY-15737

DB07268

DB07268 is a potent and selective JNK1 inhibitor with an IC₅₀ value of 9 nM.




Target: **JNK**
Effect: **Inhibitor**

(CAS No. : 929007-72-7)

HY-13022A

CC-401

CC-401 is a potent inhibitor of all three forms of JNK with K_i of 25 to 50 nM.




Target: **JNK**
Effect: **Inhibitor**

(CAS No. : 395104-30-0)

HY-15881

TCS JNK 5a

TCS JNK 5a(JNK Inhibitor IX) is a selective inhibitor of JNK2 and JNK3 (pIC₅₀ values are 6.7, 6.5, <5.0 and <4.8 for JNK3, JNK2, JNK1 and p38 α respectively); displays no significant activity at a range of other protein kinases including EGFR, ErbB2,




Target: **JNK**
Effect: **Inhibitor**

(CAS No. : 312917-14-9)

HY-10366

BI-78D3



Target: **JNK**
Effect: **Inhibitor**

(CAS No. : 883065-90-5)


(全ての製品は試験研究用です。試験研究以外の用途にはご利用いただけません。)

MAPK/ERK 伝達経路 関連化合物

~MAPK/ERK Pathway~

HY-19994

ML264




ML 264 is a potent Krüppel-like factor 5 (KLF5) inhibitor

Target: **KLF**
Effect: **Inhibitor**

(CAS No. : 1550008-55-3)

HY-12834

MK2-IN-1




MK2-IN-1 is a potent and selective MAPKAPK2(MK2) inhibitor (IC₅₀=0.11 μM) with a non-ATP competitive binding mode.

Target: **MAPKAPK2 (MK2)**
Effect: **Inhibitor**

(CAS No. : 1314118-92-7)

HY-12834A

MK2-IN-1 hydrochloride




MK2-IN-1 hydrochloride is a potent and selective MAPKAPK2(MK2) inhibitor (IC₅₀=0.11 μM) with a non-ATP competitive binding mode.

Target: **MAPKAPK2 (MK2)**
Effect: **Inhibitor**

(CAS No. : 1314118-94-9)

HY-12031

U0126




U0126 is a non-ATP competitive MEK inhibitor, with IC₅₀ of 70 nM and 60 nM for MEK1 and MEK2, respectively.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 1173097-76-1)

HY-10999

Trametinib




Trametinib is a potent MEK1/2 inhibitor that specifically inhibits MEK1/2, with an IC₅₀ value of about 2 nM.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 871700-17-3)

HY-12028

PD98059




PD98059 is an MEK inhibitor with IC₅₀ of 5 μM, also suppresses TCDD binding to the aryl hydrocarbon receptor (AHR) with IC₅₀ of 4 μM.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 167869-21-8)

HY-50706

Selumetinib




Selumetinib is a highly potent MEK inhibitor, with an IC₅₀ value of 14 nM against MEK1.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 606143-52-6)

HY-10254

PD0325901




PD0325901 (PD325901) is selective and non ATP-competitive MEK inhibitor with IC₅₀ of 0.33 nM.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 391210-10-9)

HY-18955

BI-847325




BI-847325 is an ATP competitive dual inhibitor of MEK and aurora kinases (AK) with IC₅₀ values of 4 and 15 nM for human MEK2 and AK-C, respectively.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 1207293-36-4)

HY-13064

Cobimetinib




Cobimetinib is a novel selective MEK inhibitor, and the IC₅₀ value against MEK1 is 4.2 nM.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 934660-93-2)

HY-10999A

Trametinib DMSO solvate




Trametinib DMSO solvate is a potent MEK1/2 inhibitor that specifically inhibits MEK1/2, with an IC₅₀ value of about 2 nM.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 1187431-43-1)

HY-15202

MEK162




MEK162 is a potent and selective mitogen-activated protein kinase (MEK) inhibitor with IC₅₀ of 12 nM.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 606143-89-9)

HY-N0003

Honokiol




Honokiol (NSC-293100), a hydroxylated biphenyl compound isolated from the Chinese herb Magnolia officinalis, has been reported to have anticancer activities in a variety of cancer cell lines.

Target: **MEK**
Effect: **Activator**

(CAS No. : 35354-74-6)

HY-50295

CI-1040



CI-1040 (PD184352) is an orally active, highly specific, small-molecule inhibitor of MEK with an IC₅₀ of 17 nM for MEK1.


Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 212631-79-3)

(全ての製品は試験研究用です。試験研究以外の用途にはご利用いただけません。)

MAPK/ERK 伝達経路 関連化合物

～MAPK/ERK Pathway～




HY-14691

Refametinib

Refametinib (RDEA119, BAY 86-9766), is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity (IC₅₀=19 nM MEK1; IC₅₀=47 nM MEK2).

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 923032-37-5)




HY-12467

OTS-964

OTS964 is a potent TOPK inhibitor with an IC₅₀ value of 28 nM.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 1338545-07-5)




HY-15610

GDC-0623

GDC-0623 is a potent, ATP-uncompetitive inhibitor of MEK1 (K_i=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC₅₀=42 nM) versus A375 (BRAFV600E, EC₅₀=7 nM).

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 1168091-68-6)




HY-12042

AS703026

AS703026 is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2, used for cancer treatment.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 1236699-92-5)




HY-18652

Ro 5126766

Ro 5126766 (CH5126766) is a potent and selective dual RAF/MEK inhibitor. For SK-MEL-28, SK-MEL-2, MIA PaCa-2, and SW480 cell lines, the IC₅₀ is determined by WST-8 assay is 65, 28, 40, and 46 nM, respectively.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 946128-88-7)




HY-12056

BIX02189

BIX02189 is a selective MEK5/ERK5 inhibitor with an IC₅₀ of 59 nM.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 1265916-41-3)




HY-13449

TAK-733

TAK-733 is a potent and selective MEK allosteric site inhibitor for MEK1 with IC₅₀ of 3.2 nM, inactive to Abl1, AKT3, c-RAF, CamK1, CDK2, c-Met, etc.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 1035555-63-5)




HY-12058

AZD8330

AZD8330 (ARRY-424704; ARRY-704) is a novel, selective, non-ATP competitive MEK 1/2 inhibitor with IC₅₀ of 7 nM.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 869357-68-6)




HY-14719

RO4987655

RO4987655 (CH-4987655) is an orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1/MEK1 IC₅₀=5.2 nM), with potential antineoplastic activity.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 874101-00-5)




HY-12055

BIX02188

BIX02188 is a selective inhibitor of MEK5 with IC₅₀ of 4.3 nM, also inhibits ERK5 catalytic activity with IC₅₀ of 810 nM, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 334949-59-6)




HY-15437

SL327

SL-327 is a cell-permeable vinylogous cyanamide that acts as a selective inhibitor of MEK-1 and MEK-2 (IC₅₀ = 0.18 and 0.22 μM respectively).

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 305350-87-2)




HY-12062

PD318088

PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor, binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 391210-00-7)




HY-13078

Cobimetinib racemate

Cobimetinib (GDC-0973; XL518) is a potent, highly selective inhibitor of MEK1/2.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 934662-91-6)



HY-N0776

Isorhamnetin

Isorhamnetin is an O-methylated flavonol, a flavonoid aglucon.


Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 480-19-3)

(全ての製品は試験研究用です。試験研究以外の用途にはご利用いただけません。)

MAPK/ERK 伝達経路 関連化合物

~MAPK/ERK Pathway~




HY-12202

MEK inhibitor

MEK inhibitor is a potent MEK inhibitor, antitumor agent.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 334951-92-7)




HY-10216

Refametinib R enantiomer

Refametinib R enantiomer (BAY 869766; RDEA119) is the only cyclopropane-1-sulfonamide derivative, and exhibits a highly selective allosteric inhibition of MEK 1/2.

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 923032-38-6)




HY-13079

Cobimetinib R-enantiomer

Cobimetinib R-enantiomer (GDC-0973; XL518) is the R-enantiomer of Cobimetinib, which is a potent, highly selective inhibitor of mitogen-activated protein kinase kinase (MEK1/2).

Target: **MEK**
Effect: **Inhibitor**

(CAS No. : 934660-94-3)




HY-100573

Necrosulfonamide

Necrosulfonamide is a pharmacological inhibitor of MLKL with IC50 values of 124 nM in human HT-29.

Target: **Mixed Lineage Kinase**
Effect: **Inhibitor**

(CAS No. : 1360614-48-7)




HY-12599

URMC-099

URMC-099 is an orally bioavailable, brain penetrant inhibitor of Mixed Lineage Kinase 3 (MLK3) with IC50 of 14 nM; inhibits LPS-induced TNF α release in microglial cells, HIV-1 Tat-induced release of cytokines in human monocytes, and up-regulation of

Target: **Mixed Lineage Kinase**
Effect: **Inhibitor**

(CAS No. : 1229582-33-5)




HY-100022

eFT508

eFT508 is a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor, with IC50 of 1-2 nM against both of the two isoforms.

Target: **MNK**
Effect: **Inhibitor**

(CAS No. : 1849590-01-7)




HY-10520

CGP 57380

CGP 57380 is a cell-permeable pyrazolo-pyrimidine compound that acts as a selective inhibitor of Mnk1 with IC50 of 2.2 μ M, but has no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases.

Target: **MNK**
Effect: **Inhibitor**

(CAS No. : 522629-08-9)




HY-16982

Cercosporamide

Cercosporamide is a potent and selective Mnk inhibitor, and a orally bioavailable antifungal agent, suppresses phosphorylation of eIF4E and exhibits antileukemic effects.

Target: **MNK**
Effect: **Inhibitor**

(CAS No. : 131436-22-1)




HY-10256

SB 203580

SB 203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μ M, also blocks PKB phosphorylation with IC50 of 3-5 μ M.

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 152121-47-6)




HY-10295

SB 202190

SB 202190 inhibits p38 and p38 β 2 with IC50 values of 50 nM and 100 nM.

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 152121-30-7)




HY-13241

LY2228820

LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38 α MAPK and p38 β MAPK were 7 nM and 3 nM, respectively).

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 862507-23-1)




HY-10256A

SB 203580 hydrochloride

SB 203580 hydrochloride is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μ M, also blocks PKB phosphorylation with IC50 of 3-5 μ M.

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 869185-85-3)




HY-10320

Doramapimod

Doramapimod is a highly potent p38 α inhibitor with an IC50 of 4 nM, also inhibits B-Raf with an IC50 of 83 nM and Abl with an IC50 of 14.6 μ M.

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 285983-48-4)



HY-10403

PH-797804

PH-797804 is a novel pyridinone inhibitor of p38 α with IC50 of 26 nM; 4-fold more selective versus p38 β and does not inhibit JNK2.

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 586379-66-0)


(全ての製品は試験研究用です。試験研究以外の用途にはご利用いただけません。)

MAPK/ERK 伝達経路 関連化合物

～MAPK/ERK Pathway～

HY-16715

Acumapimod




Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC₅₀ of less than 1 μ M for p38 α .

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 836683-15-9)

HY-10402

Losmapimod




Losmapimod is a selective, potent, and orally active p38 MAPK inhibitor with pK_i of 8.1 and 7.6 for p38 α and p38 β , respectively.

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 585543-15-3)

HY-100343

GNE-495




GNE-495 is a potent and Selective MAP4K4 Inhibitor with IC₅₀ of 3.7 nM.

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 1449277-10-4)

HY-10578

PD 169316




PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor (IC₅₀ = 89 nM).

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 152121-53-4)

HY-10456

TAK-715




TAK-715 is a p38 MAPK inhibitor for p38 α with IC₅₀ of 7.1 nM, 28-fold more selective for p38 α over p38 β , no inhibition to p38 γ / δ , JNK1, ERK1, IKK β , MEKK1 or TAK1.

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 303162-79-0)

HY-18306

SB 242235




SB-242235 is a potent and selective p38 MAP kinase inhibitor with IC₅₀ of 1.0 μ M.

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 193746-75-7)

HY-14975

R1487 Hydrochloride




R1487 (Hydrochloride) is highly potent and highly selective inhibitors of p38 α .

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 449808-64-4)

HY-N0674A

Dehydrocorydaline chloride




Dehydrocorydaline chloride is an alkaloidal that has anti-inflammatory and anti-cancer activities.

Target: **p38 MAPK**
Effect: **Activator**

(CAS No. : 10605-03-5)

HY-12048

Chelerythrine Chloride




Chelerythrine Chloride is a potent, cell-permeable inhibitor of protein kinase C and mitogen-activated protein kinase (MAPK), with IC₅₀ of 660 nM for PKC, competitive with respect to the phosphate acceptor and non-competitive with respect to ATP.

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 3895-92-9)

HY-10328

VX-745




VX-745 is a potent and selective inhibitor of p38 α , and possesses anti-inflammatory activity.

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 209410-46-8)

HY-10401

VX-702




VX-702 is a highly selective inhibitor of p38 α MAPK (IC₅₀=4–20 nM), 14-fold higher potency against the p38 α versus p38 β .

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 745833-23-2)

HY-11068

SB 239063




SB 239063 is a potent and selective p38 MAPK inhibitor (IC₅₀ = 44 nM for p38 α).

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 193551-21-2)

HY-10406

SCIO-469




SCIO-469 is a selective ATP-competitive p38 inhibitor with IC₅₀ of 9 nM for p38 α in vitro, about 10-fold selectivity for p38 α over p38 β , and at least 2000-fold selectivity for p38 α over an in vitro panel of 20 other kinases, including other MAK kinases.

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 309913-83-5)

HY-12839

p38 MAPK-IN-1



p38 MAPK-IN-1 is a novel potent and selective inhibitor of p38 MAPK with IC₅₀ of 68 nM, shows sustained levels, low clearance and good bioavailability.

Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 1006378-90-0)

(全ての製品は試験研究用です。試験研究以外の用途にはご利用いただけません。)


MAPK/ERK 伝達経路 関連化合物

~MAPK/ERK Pathway~

HY-14305A

BMS-582949 hydrochloride

BMS-582949 hydrochloride is a novel highly selective p38 α MAPK inhibitor, inhibits p38 α with IC50 of 13 nM.




Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 912806-16-7)

HY-10405

Pamapimod

Pamapimod is a novel p38 mitogen-activated protein kinase inhibitor.




Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 449811-01-2)

HY-100114

TA-01

TA-01 potently inhibits CK1 ϵ , CK1 δ , and p38 α (IC50 values are 6.4, 6.8, and 6.7 nM respectively).




Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 1784751-18-3)

HY-12511

SKF-86002

SKF-86002 is a potent inhibitor of p38 MAP kinase with IC50 of 0.5-1 μ M; inhibits LPS-induced IL-1 and TNF- α production in human monocytes (IC50 = 1 μ M).




Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 72873-74-6)

HY-15300

Skepinone-L

Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor.




Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 1221485-83-1)

HY-15027

5-Aminosalicylic acid

5-Aminosalicylic acid is an anti-inflammatory compound.




Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 89-57-6)

HY-100115

TA-02

TA-02 is a p38 MAPK inhibitor with IC50 of 20 nM.




Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 1784751-19-4)

HY-N0235

Bakuchiol

Bakuchiol is a phytoestrogen isolated from the seeds of Psoralea corylifolia L; has anti-tumor effects.




Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 10309-37-2)

HY-N0342

Scopoletin

Scopoletin has important anti-inflammatory activity by inhibiting the phosphorylation of NF- κ B and p38 MAPK. Scopoletin cause significant suppression of sprouting of microvessels in rat aortic explants with IC50 of 0.06 μ M.




Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 92-61-5)

HY-11087

SD-06

SD-06 is a p38 MAP kinase inhibitor; inhibits p38 α with an IC50 value of 170 nM and inhibits LPS-stimulated TNF-release in rats (83% inhibition at 1mg/kg, po).




Target: **p38 MAPK**
Effect: **Inhibitor**

(CAS No. : 271576-80-8)

HY-10201

Sorafenib

Sorafenib is a potent multikinase inhibitor with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.




Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 284461-73-0)

HY-12057

Vemurafenib

Vemurafenib is a novel and potent inhibitor of B-Raf kinase, with IC50 values of RAFV600E (31 nM) and c-Raf-1 (48 nM).




Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 918504-65-1)

HY-10201A

Sorafenib Tosylate

Sorafenib tosylate is a potent multikinase inhibitor, with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.




Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 475207-59-1)

HY-14660

Dabrafenib

Dabrafenib is an ATP-competitive inhibitor of BRAF with IC50s of 5 nM and 0.6 nM for CRAF and BRAFV600E, respectively.




Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1195765-45-7)

(全ての製品は試験研究用です。試験研究以外の用途にはご利用いただけません。)

MAPK/ERK 伝達経路 関連化合物

~MAPK/ERK Pathway~




HY-18972

PLX8394

PLX8394 is a potent and selective inhibitor of B-RafV600E (IC₅₀ 5 nM).

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1393466-87-9)




HY-18957

BGB-283

BGB-283 is a novel and potent Raf Kinase and EGFR inhibitor with IC₅₀ values of 23 and 29 nM for recombinant BRAFV600E and EGFR, respectively.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1446090-77-2)




HY-14660A

Dabrafenib Mesylate

Dabrafenib (Mesylate) is a novel, potent, and selective Raf kinase inhibitor, and inhibits the kinase activity of B-RafV600E and c-Raf with IC₅₀ values of 0.6 and 5.0 nM, respectively.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1195768-06-9)




HY-15605

LGX818

LGX818 is an orally available mutated BRAF V600E inhibitor (IC₅₀=0.3 nM) with potential antineoplastic activity.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1269440-17-6)




HY-15246

MLN 2480

MLN 2480 is an orally active and selective inhibitor of pan-Raf kinase.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1096708-71-2)




HY-12558

LY3009120

LY3009120 is a small molecule that has been shown in vitro to be a pan-RAF inhibitor of all isoforms, blocking proliferation in both BRAF and RAS mutant cells.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1454682-72-4)




HY-11004

AZ 628

AZ628 is a new pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC₅₀ of 105 nM, 34 nM and 29 nM, also inhibits VEGFR2, DDR2, Lyn, Fli1, FMS, etc.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 878739-06-1)




HY-100510

RAF709

RAF709 is a novel Raf kinase inhibitor extracted from patent WO2014151616A1, compound example 131, has an IC₅₀ of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1628838-42-5)




HY-12846

CCT196969

CCT196969, a pan-Raf inhibitor, inhibits B-Raf with an IC₅₀ of 0.1 μM.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1163719-56-9)




HY-10320

Doramapimod

Doramapimod is a highly potent p38α inhibitor with an IC₅₀ of 4 nM, also inhibits B-Raf with an IC₅₀ of 83 nM and Abl with an IC₅₀ of 14.6 μM.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 285983-48-4)




HY-51424

PLX-4720

PLX 4720 is a potent and selective inhibitor of B-RafV600E (IC₅₀=13 nM) and c-Raf-1Y340D/Y341D (IC₅₀=6.7 nM); 10-fold selectivity for B-RafV600E than wild-type B-Raf.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 918505-84-7)




HY-18997

PLX7904

PLX7904 is a potent and selective BRAF inhibitor, with IC₅₀ of approx 5 nM against BRAFV600E in mutant RAS expressing cells.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1393465-84-3)




HY-10542

GW 5074

GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC₅₀ = 9 nM); displays ≥ 100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fms.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 220904-83-6)



HY-12291

HG6-64-1

HG6-64-1 is a potent and selective B-Raf and mutant B-Raf inhibitor; more information can be found in Patent WO 2011090738.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1315329-43-1)


(全ての製品は試験研究用です。試験研究以外の用途にはご利用いただけません。)

MAPK/ERK 伝達経路 関連化合物

~MAPK/ERK Pathway~

HY-18652

Ro 5126766




Ro 5126766 (CH5126766) is a potent and selective dual RAF/MEK inhibitor. For SK-MEL-28, SK-MEL-2, MIA PaCa-2, and SW480 cell lines, the IC₅₀ is determined by WST-8 assay is 65, 28, 40, and 46 nM, respectively.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 946128-88-7)

HY-13343

ZM 336372




ZM 336372 is a potent and selective c-Raf inhibitor with IC₅₀ of 70 nM, 10-fold selectivity over B-Raf, no inhibition to PKA/B/C, AMPK, p70S6, etc.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 208260-29-1)

HY-15767

TAK-632




TAK-632 is a potent pan-RAF inhibitor with IC₅₀ of 1.4, 2.4 and 8.3 nM for CRAF, BRAFV600E, BRAFWT, respectively.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1228591-30-7)

HY-10248

RAF265




RAF265 (CHIR-265) is a potent selective inhibitor of C-Raf/B-Raf/V-Raf V600E with IC₅₀ of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC₅₀ of 30 nM.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 927880-90-8)

HY-50864

GDC-0879




GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC₅₀ of 0.13 nM with activity against c-Raf as well; no inhibition known to other protein kinases.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 905281-76-7)

HY-14177

B-Raf inhibitor 1




B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC₅₀s of 0.31 μM and 2 nM for A375 proliferation and A375 p-ERK respectively.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1093100-40-3)

HY-18227

B-Raf IN 1




B-Raf IN 1 is a highly potent and selective B-Raf inhibitor with IC₅₀ of 24 nM; equipotent against c-Raf (IC₅₀ = 25 nM).

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 950736-05-7)

HY-10247

BRAF inhibitor




BRAF inhibitor is a potent BRAF inhibitor.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 918505-61-0)

HY-12787

L-779450




L-779450 is a potent, ATP-competitive Raf kinase inhibitor (IC₅₀ = 10 nM) that displays > 7, > 30 and > 70-fold selectivity over p38α, GSK3β and Lck respectively.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 303727-31-3)

HY-15200

CEP-32496




CEP-32496 is a highly potent inhibitor of BRAF (V600E/WT) and c-Raf with K_d of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1188910-76-0)

HY-10966

SB-590885




SB590885 is a potent B-Raf inhibitor with K_i of 0.16 nM, 11-fold greater selectivity for B-Raf over c-Raf, no inhibition to other human kinases.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 405554-55-4)

HY-15199

CEP-32496 hydrochloride




CEP-32496 HCl is a highly potent inhibitor of BRAF (V600E/WT) and c-Raf with K_d of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1227678-26-3)

HY-77251

B-Raf inhibitor




A B-Raf inhibitor, pyrazine and pyrrolo[2,3-b]pyridine derivatives, useful in the treatment of cancer and proliferative diseases.

Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1315330-11-0)

HY-14177A

B-Raf inhibitor 1 dihydrochloride



B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC₅₀s of 0.31 μM and 2 nM for A375 proliferation and A375 p-ERK respectively.


Target: **Raf**
Effect: **Inhibitor**

(CAS No. : 1191385-19-9)

(全ての製品は試験研究用です。試験研究以外の用途にはご利用いただけません。)

MAPK/ERK 伝達経路 関連化合物

~MAPK/ERK Pathway~



HY-15431


AZD5363

AZD5363 is a potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1,2 and 3, respectively.

Target: **Ribosomal S6 Kinase (RSK)**

Effect: **Inhibitor**

(CAS No. : 1143532-39-1)



HY-52101


CMK

CMK is a RSK2 kinase inhibitor, used for cancer treatment.

Target: **Ribosomal S6 Kinase (RSK)**

Effect: **Inhibitor**

(CAS No. : 821794-90-5)



HY-10510


BI-D1870

BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3 β , MARK3, CK1 and Aurora B.

Target: **Ribosomal S6 Kinase (RSK)**

Effect: **Inhibitor**

(CAS No. : 501437-28-1)



HY-52101A


FMK

FMK is a RSK2 kinase inhibitor.

Target: **Ribosomal S6 Kinase (RSK)**

Effect: **Inhibitor**

(CAS No. : 821794-92-7)



HY-10579


Pluripotin

Pluripotin (SC-1) inhibits in vitro kinase activity of RSK2 with EC50 of 2.5 \pm 1.8 μ M.

Target: **Ribosomal S6 Kinase (RSK)**

Effect: **Inhibitor**

(CAS No. : 839707-37-8)



HY-15773


PF-4708671

PF-4708671 is a novel cell-permeable inhibitor of S6K1 (p70 ribosomal S6 kinase 1), with a Ki of 20 nM and IC50 of 160 nM.

Target: **Ribosomal S6 Kinase (RSK)**

Effect: **Inhibitor**

(CAS No. : 1255517-76-0)



HY-16104


BIX 02565

BIX 02565 is a potent ribosomal S6 kinase 2 (RSK2) inhibitor with IC50 of 1.1 nM.

Target: **Ribosomal S6 Kinase (RSK)**

Effect: **Inhibitor**

(CAS No. : 1311367-27-7)



HY-19713


LJI308

LJI308 is a new and potent pan-RSK inhibitor, with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.

Target: **Ribosomal S6 Kinase (RSK)**

Effect: **Inhibitor**

(CAS No. : 1627709-94-7)



HY-19712


LJH685

LJH685 is a potent, specific and selective RSK inhibitor; inhibits RSK1, 2, and 3 biochemical activities with IC50 of 4 to 13 nM.

Target: **Ribosomal S6 Kinase (RSK)**

Effect: **Inhibitor**

(CAS No. : 1627710-50-2)



HY-12493


LY-2584702 free base

LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes.

Target: **Ribosomal S6 Kinase (RSK)**

Effect: **Inhibitor**

(CAS No. : 1082949-67-4)



HY-12493A


LY-2584702 tosylate salt

LY-2584702 tosylate salt is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes.

Target: **Ribosomal S6 Kinase (RSK)**

Effect: **Inhibitor**

(CAS No. : 1082949-68-5)



HY-B0405A


Bupivacaine hydrochloride

Bupivacaine Hydrochloride is a local anaesthetic drug belonging to the amino amide group.

Target: **Ribosomal S6 Kinase (RSK)**

Effect: **Inhibitor**

(CAS No. : 18010-40-7)



HY-N0418


Quercitrin

Quercitrin is a natural compound found in Tartary buckwheat with a potential anti-inflammation effect that is used to treat heart and vascular conditions.

Target: **Ribosomal S6 Kinase (RSK)**

Effect: **Inhibitor**

(CAS No. : 522-12-3)



HY-12493B

LY-2584702 hydrochloride

LY-2584702 Hcl is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes.

Target: **Ribosomal S6 Kinase (RSK)**

Effect: **Inhibitor**

(CAS No. : 1082948-81-9)

(全ての製品は試験研究用です。試験研究以外の用途にはご利用いただけません。)